Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response after Out-of-Hospital Cardiac Arrest (IMICA): study protocol for a randomized clinical trial

Background: Resuscitated out-of-hospital cardiac arrest (OHCA) patients who remain comatose at admission are at high risk of morbidity and mortality. This has been attributed to the post-cardiac arrest syndrome (PCAS) which encompasses multiple interacting components, including systemic inflammation. Elevated levels of circulating interlukin-6 (IL-6), a pro-inflammatory cytokine, is associated with worse outcomes in OHCA patients, including, higher vasopressor requirements and higher mortality rates. For other indications, an IL-6 receptor antibody, tocilizumab has been approved. In this study we aim to reduce systemic inflammation after OHCA by administering a single infusion of tocilizumab. Methods: Investigator-initiated, randomized, double blind, placebo-controlled clinical trial in OHCA patients remaining unconscious after hospital admission. Intervention: Intravenous administration of an interleukin-6 receptor antibody (IL-6RA), tocilizumab, or placebo after admission. Primary endpoint: reduction in C-reactive protein (CRP). Secondary endpoints (abbreviated): cytokine levels, markers of brain, cardiac, kidney and liver damage, and hemodynamic and haemostatic function, adverse events, as well as follow-up assessment of cerebral function and mortality. Discussion: We hypothesise that reducing the effect of circulating IL-6 by administering an IL-6 receptor antibody will mitigate the systemic inflammatory response and thereby modify the severity of PCAS, in turn leading to decreased need of vasopressor support, more normal hemodynamics, as well as better organ function. A previous trial of IL6-RA in patients with non-ST elevation myocardial infarction showed a reduction in CRP and troponin levels, as well as a change in

cytokine levels. Following these findings, we will be measuring a range of both proinflammatory and anti-inflammatory cytokines to possibly reveal a change in cytokine patterns following blockage of the IL-6 receptor, as well as investigate whether IL-6RA leads to reduced organ damage. Infection after OHCA is not uncommon and IL6-RA has previously been shown to increase the frequency of infections. Accordingly, we will monitor for infections, and patients will be treated with prophylactic antibiotics.

Background and rationale {6a}
Resuscitated out-of-hospital cardiac arrest (OHCA) patients who remain comatose at admission are at high risk of morbidity, and mortality remains above 50% at 30days [1]. Consequently, an increasing emphasis on post-resuscitation care has been addressed by current guidelines [2,3].
The high mortality in comatose OHCA patients has been attributed to the postcardiac arrest syndrome (PCAS), which includes four mutually interacting components: systemic ischemia/reperfusion response, cerebral injury, myocardial dysfunction, and the persistent precipitating cause of the arrest [4]. Despite repeated emphasis on post-resuscitation care, no specific therapies targeting PCAS have been implemented except targeted temperature management (TTM), which has been recommended since 2003 [5]. Thus, research addressing mitigation of the PCAS is warranted. During OHCA, patients are exposed to whole-body ischemia, which is ensued by reperfusion injury after resuscitation, both of which trigger activation of inflammatory cascades leading to a systemic inflammatory response or sepsis-like syndrome [6][7][8][9]. High levels of Inflammatory markers, including procalcitonin (PCT) [9][10][11], C-reactive protein (CRP) [9], interleukin (IL) 6 [9], and IL-10 [9], have been associated with unfavorable outcome after OHCA. Furthermore, the inflammatory markers interleukin 1β (IL-1β), IL-6, IL-10, and tumor necrosis factor α (TNF-α) have all been associated with the severity of PCAS, assessed by sequential organ failure assessment (SOFA) score in unconscious OHCA patients [8].
Importantly, levels of IL-6 have been shown to be independently associated with poor outcomes in unconscious OHCA patients after adjustment for known risk markers [9]. Further, the level of IL-6 was more strongly associated with PCAS severity compared to classical inflammatory markers such as CRP and PCT [8].
IL-6 is a pro-inflammatory cytokine secreted by T cells and macrophages. IL-6 readily crosses the blood-brain-barrier [12] and is a mediator of fever. Further, IL-6 is a mediator of the acute phase response and plays a role in activation of the coagulation system, increasing vascular permeability, and weakening papillary muscle contractions leading to myocardial dysfunction [13]. IL-6 has been found to be involved in range of pathological processes including tissue hypoxia, disseminated intravascular coagulation (DIC), and multiorgan failure [13], all of which represent parts of the SIRS response. IL-6 has been suggested to play a role in ischemia-reperfusion injury in myocardial infarction (MI), and higher levels of IL-6 have been associated both with the magnitude of myocardial injury, mortality and adverse events in this group [14][15][16].
Due to the role of IL-6 in many inflammatory diseases, IL-6 receptor antibodies (IL-6RA) have been developed. The first IL-6RA, tocilizumab, was approved for   treatment of rheumatoid arthritis in 2009, and has later been approved for giant cell   arthritis and chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome. In addition to the approved indications, tocilizumab has been suggested to have other beneficial immune modulating and organ protective effects against the autoimmune neurological disorders neuromyelitis optica and autoimmune encephalitis [17][18][19][20]. In patients presenting with non-ST-elevation myocardial infarction (NSTEMI), a one-hour infusion of 280mg tocilizumab decreased the inflammatory response assessed by CRP levels, and further decreased myocardial injury assessed by TnT levels [21]; importantly, no increased risk of adverse events was observed in patients receiving tocilizumab. Animal data suggest that tocilizumab is safe and effective for treatment of severe acute pancreatitis and associated acute lung injury [22]. Further, tocilizumab had neuroprotective effects in a model of Alzheimer disease [23].
In summary, resuscitated OHCA is associated with a systemic inflammatory response, the magnitude of which has been associated with increased mortality and poor neurological outcome. IL6 was associated with the severity of PCAS and mortality in the large Target Temperature Management (TTM) Trial in OHCApatients. Inhibiting the IL-6 mediated immune response by infusion of the IL6RA Tocilizumab in the acute phase after hospital admission may mitigate the systemic inflammatory response and may further inhibit ischemia-reperfusion injury possibly leading to improved outcomes.

Objectives
Primary objective: The primary objective of this study is to determine the efficacy of an interleukin-6 (IL-6) receptor antibody (IL-6RA) compared with placebo on the endpoint of daily high-sensitivity c-reactive protein (hsCRP) measurements from admission (i.e. prior to initiation of study drug) to the first 72 hours after admission in comatose patients admitted after resuscitated OHCA.
Secondary objective: The secondary objectives of this study are to determine the effects of an IL-6RA on inhibition of inflammation, cardiac protection, neuroprotection, renal protection, endothelial protection, clinical endpoints including survival and neurological outcome, as well as safety.
Hypothesis:A one-hour infusion of the IL-6RA tocilizumab initiated as soon as possible after ROSC will reduce the SIRS-like response assessed by hsCRP levels in unconscious OHCA patients.

Trial Design
This is an investigator-initiated, randomized, placebo-controlled, double-blinded clinical phase II trial. Following successful completion of screening procedures, subjects will be randomized in a 1:1 fashion to receive IL-6RA or placebo.

Study setting {9}
Single centre study carried out at the Cardiac Intensive Care Unit within the Department of Cardiology, The Heart Centre, Copenhagen University Hospital -Rigshospitalet, Copenhagen.

Eligibility criteria {10}
From trial initiation, a screening log will be completed on a day-to-day basis including limited information about each potential study candidate (i.e. initials, age, sex, race), date, and outcome of the screening (i.e. enrolled, reasons for ineligibility, refusal to participate, etc.). Screening will be performed by the physician on call or a dedicated team of research personnel, all medical doctors.
After inclusion in the study by a qualified medical doctor, infusion of the study drug will be managed by the attending ICU nurse.
Inclusion in the IMICA trial does not prohibit participation in other trials, and the vast majority of patients are also expected to be enrolled in the multi-center randomized trial "Blood Pressure and OXygenation Targets After OHCA (BOX)", which investigates the optimum targets for blood pressure and oxygenation after OHCA, and investigate an automated feedback temperature control-device for fevercontrol duration of targeted temperature management; ClinicalTrial.gov identifier: NCT03141099.

Inclusion Criteria
Each of the following criteria must be fulfilled for a subject to be eligible: Who will take informed consent? {26a} The trial will be conducted in accordance with the Declaration of Helsinki and follow EU and national legislation on medical research in subjects in emergency situations being temporarily incapacitated. All subjects are incapacitated according to the inclusion criteria. Thus, subjects will not be able to provide informed consent.
National legislation requires proxy consent from a legal surrogate, in this trial, a medical doctor with no involvement in the patient treatment, as well as consent from the next of kin. The legal surrogate will be consented prior to inclusion in the study, and the next of kin at the earliest possible time. Consent will be obtained by the physician on call or a dedicated team of research personnel, all medical doctors.
Additional consent provisions for collection and use of participant data and biological specimens {26b} The use of patient data or biological specimens for ancillary studies will be dependent on approval from the local ethical committee unless this is waived based on prior approvals or the design of the studies.

Interventions Explanation for the choice of comparators {6b}
Aiming for an attenuation of the systemic inflammatory response after OHCA by use of an IL-6RA, tocilizumab we have chosen to give a single 1-hour infusion of tocilizumab 1mg/kg (maximum 800mg) as this is the dosage used for repeated infusions in rheumatoid arthritis, an already approved indication [24].

Intervention description {11a}
Patients being allocated to IL-6RA will receive a one-hour infusion of 8 mg tocilizumab per kg body weight (maximum dose 800 mg, 40 mL), equivalent to 0.4 mL per kg bodyweight (study drug concentration 20 mg/mL), the study drug will be suspended in normal saline to a total volume of 100mL. Patients being allocated to placebo will receive a one-hour infusion of 100mL of normal saline. The infusion of either IL-6RA or placebo will commence at the earliest possible time after admission and study inclusion.

Criteria for discontinuing or modifying allocated interventions {11b}
A subject or the subjects next of kin has the right to withdraw from the study at any time, for any reason, without prejudice to his or her future medical care by the physician or at the institution. Any subject who withdraws consent to participate in the study will immediately be removed from further treatment and/or study observation on the date of request. In addition, the investigator and the sponsor have the right to withdraw a subject from the study if any of the following occurs: 1.Significant intercurrent illness 2.Refusal by the subject to continue observations 3.Decision by the investigator that termination is in the subject's best medical interest Should a subject (or legally acceptable representative) request or decide to withdraw from the study, all efforts will be made to complete and report the observations as thoroughly as possible up to the date of withdrawal. All information should be reported on the applicable case report forms. A complete final evaluation and assessments (section 7.4) should be made at the time of the subject's withdrawal. The End of Study case report form will be completed with an explanation for the withdrawal. If the withdrawal of a subject is due to an adverse event, follow-up visits should be scheduled until the adverse event has resolved or stabilized. Unless consent has been withdrawn, follow-up data on deaths and hospitalizations will be collected until study termination or a maximum of 48 months since enrolment of the subject. Unless specifically requested by the patient, the patient will be followed for the primary endpoint until end of study. There are no restrictions in concomitant care for trial participants and the specific care of all subjects is left to the discretion of the treating physician.
Patients will be treated with standard therapies for OHCA according to contemporary guidelines and necessary cardiac interventions will not be delayed by the trial intervention; however, efforts will be made to maintain study drug infusion during treatment.
Provisions for post-trial care {30} Participating subjects will be insured by the health system responsible for the trial site, "Rigshospitalet".
Secondary Endpoints: Markers of inflammation:

Sample size {14}
The trial is powered at the primary endpoint. A previous trial has shown an effect of tocilizumab on hsCRP in NSTEMI patients [21].

Sequence generation {16a}
Successfully screened subjects will be randomized into the study by the investigator, or assigned co-investigator, who will access a secure prefabricated randomization website, enter patient identification data and complete a checklist with in-and exclusion criteria. A computer-generated allocation sequence will then assign treatment arm in permuted blocks of four.

Concealment mechanism {16b}
The treatment assignment is managed by the above described website and information on specific treatment assignment is during the trial only available for the nurse who prepares the study drug as described below. After completion of the study drug for each patient a document with assignment, information on lotnumbers, dosage and who prepared it is completed and stored in a sealed envelope.

Implementation {16c}
After randomization of each subject, the doctor who randomized or the attending ICU nurse will contact a prespecified neighbouring department and request preparation of the study drug. Only the nurses at the neighbouring department who are responsible for preparing the study drug will be able to access the randomization website with specific log-in credentials and see the assigned treatment of either active (IL-6RA / RoActemra) or placebo (NaCl).
The investigator will only after completion of the trial receive a computer-generated code regarding treatment assignment 'A' or 'B' and at the time of unblinding be informed of which is active / placebo.

Assignment of interventions: Blinding
Who will be blinded {17a} Clinical personnel, research personnel and patients, except for the nurses who prepares the study drug (not involved in patient care, see below), will be blinded to the assigned interventions during the study period. For data analysis, assignments will be labelled "A" and "B", and only after completion of the calculations will assignments be unblinded.

Procedure for unblinding if needed {17b}
The identification of treatment allocation will be maintained at a computer located at Rigshospitalet, protected from participants of the study. Authorized site staff will be provided with a unique Personal Identification Number (PIN) to obtain unblinding information.
For each subject, after preparation of the study drug a document is filled out with information on treatment allocation, lot numbers and who prepared it as described above; this document is then stored in a concealed envelope and should only be opened after the trial has been completed and unblinding is intended or on a patient specific basis as described below; these envelopes will also be available for monitoring agencies who will then reseal after monitoring. A subject's treatment assignment should only be unblinded by a study site when knowledge of the treatment is essential for the further management of the subject or if needed for safety reporting to regulatory authorities. Unblinding at the study site for any other reason will be considered a protocol deviation.
For unblinding at the site, the Principal Investigator should if possible be contacted before unblinding any subject's treatment assignment. At the latest, the sponsorinvestigator must be notified within 1 working day after the event, and the unblinding must be documented in the subject's case report form.

Data collection and management
Plans for assessment and collection of outcomes {18a} Patient data will be handled as ordinary chart records. All data will be kept according to national legislation. The study database will be constructed in REDCap® in accordance with national legislation and local practice. The database will be maintained for 15 years and anonymized if requested by relevant authorities.
Data from analysis of biomarkers from the biobank will be stored on an approved server with back-up function.
Data entries in RedCap will be monitored by a Good Clinical Practice (GCP) unit as described below.

Plans to promote participant retention and complete follow-up {18b}
During the initial 3 days after admission, where the majority of data collection, and all blood sampling, are scheduled the majority of patients are expected to remain within the Cardiac ICU where the study is harboured; those who experience an expedited recovery and are moved out of the ICU to a neighbouring ward will be sought sampled for blood as well; only a minority of patients are expected to be transferred to another hospital within the initial three days, however these patients can not be sampled for the biobank, yet any routine biochemistry, including CRP, can be accessed by use of a shared electronic medical file. For follow up the contact information for patients and their next of kin are stored with the intention of inviting patients to a "90 days follow up evaluation" at Rigshospitalet. Those who can not or will not come to the hospital will receive a follow up questionnaire by letter. Finally, after 180 days patients or next of kin will be contacted by phone for a brief cognitive evaluation; finally both the regional medical file and the joint national medical file will be used for evaluation as well.

Data management {19}
See "Plans for assessment and collection of outcomes" above

Confidentiality {27}
As listed above all data will be kept according to national legislation, with data from ordinary medical charts entered in REDCap®, and results from analysis of biobank material will be kept on a secured server. Data will only be shared based on approval from the relevant authorities.
Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33} A biobank will be kept according to the granted approvals, and planned analyses as listed in "outcomes" section will be carried out at an experienced laboratory. Future studies will be able to access this pertinent on approval from relevant authorities.
At this time no genetic studies are planned.

Statistical Methods
Statistical methods for primary and secondary outcomes {20a} All analyses will be conducted on the modified intention-to-treat population with a set significance level of 0.05. Throughout, categorical variables will be presented as numbers (frequencies), whereas continuous variables will be presented as mean ±standard deviation (SD) if normally distributed, and as median (25 th percentile-75 th percentile) if non-normally distributed.

Analysis of continuous endpoints
Continuous endpoints being assessed at multiple time points (including the primary endpoint) will be analyzed by application of linear mixed models of covariance. The main result of these analyses will be the treatment-by-time interaction as a marker of whether the individual endpoint changes differently over time in the tocilizumab versus the placebo arm. As admission blood samples are scheduled to be drawn prior to study infusion, baseline correction will be employed as appropriate.
Logarithmic transformation will be applied to approximate normal distribution as appropriate. The application of linear mixed models of covariance for analysis of the primary endpoint will result in a somewhat higher power as compared to the sample size calculation (see above) being based on a single measurement. As many trials apply a power of 0.90 for sample size calculations, we deem this acceptable. In case of missingness greater than 5% for the primary endpoint, multiple imputations by chained equations will be applied as sensitivity analysis with generation of 20 individual data sets.

Analysis of categorical endpoints
Categorical endpoints by treatment allocation will be analyzed by the Chi-Squared or the Fisher's exact test, as appropriate.

Analysis of survival data
Kaplan-Meier curves for each allocation group will be estimated, graphically displayed, and compared by the log-rank test. Further Cox proportional hazard models will be applied to assess differences in time to death between treatment groups. These models will sequentially be adjusted for the interaction between treatment allocation, and each of the following variables: sex, age, time to ROSC, lactate level upon admission, shockable primary rhythm, STEMI upon admission, pPCI performed, and levels of inflammatory markers including IL-6 and hsCRP.
Further, models stratified by cause of death (cardiovascular, neurological, multiorgan failure) will be applied as hypothesis generating. Any changes from the pre-specified analysis plan will be reported.

Interim analyses {21b}
As this is a pilot trial with a limited number of planned inclusions no interim analysis will be performed, however the sponsor-investigator will closely monitor the general safety of the trial participants.
Methods for additional analyses (e.g. subgroup

analyses) {20b}
With respect to analyses of whether IL-6RA reduces infarction size after STelevation myocardial infarction this will only be investigated in a subgroup of patients with an acute coronary angiogram indicating this condition.
Also the interaction of time to ROSC and time to infusion of the study drug on the changes in markers of inflammation compared to placebo will be investigated; for this patients will be divided in two groups, below/above the median time to ROSC and time to infusion.
Further the effects on the coagulation system by the study drug compared to placebo will be investigated by daily fibrinogen measurements and thrombelastography at admission and at 48hour; specifically, we will investigate if these differences between active and placebo are more pronounced in patients with hyperfibrinolysis.
Methods in analysis to handle protocol nonadherence and any statistical methods to handle missing data {20c} All analyses will be made on the modified intention to treat population, i.e.
randomized patients for whom the study drug has been prepared and the patients next of kin has not refused participation when informed of the study and asked for consent.
As listed above, missingness of greater than 5% for the primary outcome (hsCRP) will prompt the use of multiple imputation.
Plans to give access to the full protocol, participant level-data and statistical code {31c} The full protocol will be available upon reasonable request. Participant level-data will be made available upon reasonable request after full publication and approvals from relevant authorities.

Oversight and monitoring
Composition of the coordinating centre and trial steering committee {5d} The IMICA trial is a single-center study, initiated and overseen by the sponsorinvestigator. See below for further.
Composition of the data monitoring committee, its role and reporting structure {21a} Yearly safety rapports will be filed to the Local Ethical Committee and Danish Medicines Agency, and patient safety will be monitored closely by the sponsorinvestigator and co-investigators, however as this is a trial of limited size no data monitoring committee will be formed.

Adverse event reporting and harms {22}
Adverse events will be assesed daily for the first 7 days and adverse events occurring after day 7 will be evaluated at 30 and 180 day follow-up. At each assessment of all adverse events, serious adverse events (SAE) and suspected unexpected serious adverse reactions (SUSAR) must be recorded by the investigator and evaluated. Each SAE and SUSAR requires the sponsor to fill in the AE form, including the following variables: description of event, onset and end of event, severity, relation to the intervention, action taken, and outcome. Any adverse events occurring during the study will be treated according to established standards, and the subject will be followed until the event has disappeared or stabilized. On a yearly basis, a safety rapport containing information on serious adverse events/reactions will be submitted to the Danish Health and Medicines Authority.
prolongation of hospitalization, or results in significant disability, including congenital anomaly or birth defect.
For each AE the investigator assesses potential causality between investigational product, and whether the reaction is suspected will be assessed by the sponsor. The Summary of Product Characteristics for RoActemra will be used for this assessment.
The sponsor will be responsible to report all life-threatening of lethal SUSARS to the Danish Health and Medicines Authority as soon as possible and no later than 7 days after being aware of such an event. Non-life-threatening SUSARs will be reported as soon as possible and no later than 15 days after the event.
Frequency and plans for auditing trial conduct {23} The trial will be externally monitored by national Good Clinical Practice (GCP) unit at the Copenhagen GCP center. A monitoring plan will be conducted prior to trial initiation. The frequency of onsite monitoring will depend on compliance with the protocol, number of enrolled patients, and quality of data handling. There will be mandatory monitoring before and after the trial and at least once during the trial.
The GCP will monitor inclusion and exclusion criteria, consent obtained in all subjects according to legislation, and data included in the eCRF. The principal investigator will be responsible for all data in the eCRFs.
Plans for communicating important protocol amendments to relevant parties (e.g. trial

participants, ethical committees) {25}
Major protocol modifications and related changes to patient information will only be implemented after approval from regulating authorities as appropriate.

Dissemination plans {31a}
The results of the trial will be submitted for publication in international peer reviewed journals and submitted for presentation at international conferences.
Patients and their next of kin are asked at the time of consent if they would like to receive the results of the trial when completed.

Discussion
In this study we aim to reduce the biological effects of circulating IL-6 by administering tocilizumab at an early timepoint after OHCA to possibly dampen the systemic inflammatory response seen after OHCA. Previous studies have found that high plasma levels of IL-6 are associated with a greater need of vasopressor support after OHCA [28], and higher degree of endothelial activation and injury [29] and correlated with the degree of PCAS estimated by SOFA-score [8], and ultimately was associated with mortality [9]. Whether these findings of an association between higher levels of IL-6 is associated with morbidity and mortality predominantly reflects the nature of the resuscitation attempt or constitutes a causal component in triggering development of PCAS is unknown. However, mitigating the inflammatory response at this early stage might modify the severity of PCAS in turn possibly leading to less vasoplegia/decreased need of vasopressor support, more normal CO and SVR findings as well as better organ function.
A previous randomized trial of the use of IL6-RA in NSTEMI patients has shown a reduction in hsCRP and troponin levels [21], as well as a change in cytokine levels in patients treated with a dose smaller dose of IL6-RA than in the IMICA trial [30].
The degree of systemic inflammation in these NSTEMI patients were much lesser than observed after OHCA and likely the effects of IL-6RA will be of a different magnitude in the present trial, likewise a substantial proportion of OHCA patients in this trial will present with STEMI, again leading to higher levels of myocardial injury and troponin release. Inspired by these findings we will be conducting an extensive measurement of a wide range of both pro-inflammatory and anti-inflammatory cytokines to possibly reveal a change in cytokine patterns following pharmaceutical blockage of the IL-6 receptor, as well as investigate whether IL-6RA leads to lessened troponin release in OHCA patients, including those with myocardial infarction.
Infection after OHCA is not uncommon [31][32][33][34], including in cases of presumed cardiac cause. IL6-RA has previously been shown to increase the frequency of infections in a randomized trial in rheumatoid arthritis [35]. Patients in IMICA will be monitored for infections, including sampling of tracheal secretion early after admission, and will be treated with prophylactic antibiotics (intravenous piperacillin/tazobactam, or cefuroxime in case of beta-lactam allergy) as part of routine therapy. Patients will be advised of a possible reduced immune function for a short duration after the treatment with tocilizumab/placebo, and this will also be noted in the medical file.
This trial has been powered to detect a 30% reduction in hsCRP 48 hours after OHCA. If this primary endpoint is achieved, we will investigate possible downstream Declarations regulating authorities, and approved this manuscript.
JG: Co-investigator, participates in the conduct of the trial and data collection.
JK: Head of the Cardiac ICU where the trial is carried out, co-investor, co-drafted protocol, participates in the conduct of the trial.
CH: Sponsor-investigator, co-drafted the original protocol, is overall responsible for the initiation and conduct of the trial.
All authors read and approved the final manuscript

Funding {4}
The funding bodies listed below has had and will have NO role in the design of the study and collection, analysis, and interpretation of data and in writing this or future manuscript concerning the IMICA trial.

Availability of data and materials {29}
Not applicable.

Ethics approval and consent to participate {24}
The study will be conducted in adherence to national and international standards of good clinical practice (GCP). The protocol including amendments, as well as written information and consent forms will be submitted to the regional ethics committee for review and approval prior to initiation of the trial.
Eligible subjects are unconscious, and accordingly incapacitated to give informed consent in the acute setting. Since IL-6RA are thought to reduce the SIRS-like response escalating from OHCA, study drug infusion needs to be initiated as soon as possible. Accordingly, randomization is thought to be justified prior to subject informed consent, according to the Helsinki Declaration, Section 2.5. Thus, in accordance with national legislation, informed consent will be obtained from a legal surrogate prior to randomization in the trial. The legal surrogate no. 1 will be the attending doctor with function of trauma leader at the Trauma Center, Rigshospitalet. The next of kin will be asked for informed consent as soon as possible. On the first coming weekday, consent will be obtained from legal surrogate no. 2. Legal surrogate no. 2 will be an attending doctor at the Intensive Care Department 4131. If a subject regains consciousness, he or she will be asked for informed consent.

Consent for publication {32}
Not applicable.